• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

    6/29/23 7:00:00 AM ET
    $NEO
    Precision Instruments
    Health Care
    Get the next $NEO alert in real time by email

    FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.

    The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was acquired by Illumina in 2022, will be a member of the Culture & Compensation and Nominating and Corporate Governance Committees. Tony Zook, former Chief Executive Officer of Innocoll Pharmaceuticals, a pharmaceutical manufacturing company focused on postsurgical pain management, will be a member of the Audit & Finance and Culture & Compensation Committees. The three join a strong, independent board with world-class talent and unique and differentiated skillsets.

    "Elizabeth, Neil and Tony collectively bring more than 50 years of executive experience in healthcare, which will broaden the skills of our current Board, especially in the fields of digital technologies, global marketing and molecular diagnostics" said Lynn Tetrault, Chair of the Board of Directors. "We welcome Elizabeth, Neil and Tony to the board at this pivotal time for the company and look forward to working with them to drive long term, sustainable and profitable growth for the benefit of all of our stakeholders."

    "Our new board members are seasoned business leaders whose public company experience and financial acumen will be valuable to our Board as the company continues to execute on its vision," said Chris Smith, Chief Executive Officer of NeoGenomics.

    New Independent Director Biographies

    Elizabeth Floegel has a track record for successfully leading technology and organizational transformation in highly matrixed environments. As Chief Information & Digital Officer of Numotion, Elizabeth is managing a significant digital and cybersecurity transformation with the strategic use of data and technology to drive value creation by creating efficient and compliant operations. Before joining Numotion, Ms. Floegel was the Global Vice President of Business Technology at Allergan (now part of Abbvie). In her time at Allergan, she led the technology portfolio across global commercial, retail, digital products and marketing. Ms. Floegel's earlier roles include Head of Commercial and Digital Technology for Regeneron Pharmaceuticals and Global Vice President of Commercial Technology for Baxter Healthcare.

    Neil Gunn is a veteran Diagnostics senior executive with expertise in company organization to maximize efficiencies with a focus on value generators to drive growth. Most recently, Neil was the Chief Executive Officer of IDbyDNA, which was acquired by Illumina in 2022. Prior to that, Dr. Gunn was President of Roche Sequencing Solutions (RSS), where he grew the organization from early initial concepts to over 900 employees across three continents while integrating nine acquisitions into one with a common vision and strategy. Before RSS, Dr. Gunn was Head of Global Business for Roche Molecular Diagnostics (RMD) and was responsible of the development and execution of strategic plan that launched over 140 major assay, instrument, and software launches over six years. Neil's earlier roles include Vice President Commercial Operations for CaridianBCT and Vice President of Commercial Operations - Americas for Novartis Diagnostics.

    Tony Zook has significant experience as a brand and marketing executive with a focus on managing interface between commercial and research and development aspects of an organization. Prior to serving as Chief Executive Officer of Innocoll Pharmaceuticals, Tony was Executive Vice President, Commercial Operations of AstraZeneca (AZ) where he held global P&L responsibility for all of AZ's brands and markets. Under Tony's leadership, AZ commercialized ten brands, each in excess of $1 billion in sales. Tony was also responsible for MedImmune, AZ's global biologics business. He also chaired the Commercial Investment Board, which identified and approved critical investments company-wide, including investments in plants, markets, and technology. Earlier in his career at AZ, Mr. Zook held various positions including CEO of North America and VP of Sales, where he helped lead the integrations of Astra US, Astra Merck, and Zeneca. Prior to joining AZ, Mr. Zook spent 14 years with Berlex Laboratories in a variety of positions.

    About NeoGenomics, Inc.

    NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.

    NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all applicable state and federal data protection laws, provides transparency and choice to patients regarding the handling and use of their data through expressed authorizations and our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.

    Forward Looking Statements

    This press release includes forward-looking statements. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 24, 2023 as well as other information previously filed with the SEC. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements.

    NeoGenomics, Inc.

    Kendra Sweeney
    Vice President, Investor Relations and Communications
    [email protected]
    T: +1-239-877-7474

    SOURCE: NeoGenomics, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/764483/NeoGenomics-Expands-Board-of-Directors-with-Appointments-of-Three-Independent-Directors

    Get the next $NEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEO

    DatePrice TargetRatingAnalyst
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    1/13/2025Buy → Hold
    The Benchmark Company
    12/10/2024$22.00Buy
    Jefferies
    5/1/2024$26.00Buy
    Craig Hallum
    12/29/2023$25.00 → $21.00Buy
    BTIG Research
    8/21/2023$18.00Equal-Weight → Overweight
    Stephens
    5/16/2023Outperform → Mkt Perform
    Raymond James
    5/9/2023$25.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeoGenomics Pays Off 1.25% Convertible Senior Notes

      NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced that it has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes with a maturity date of May 1, 2025, using cash on hand. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predict

      5/1/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

      FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance NeoGenomics' ability to offer innovative clinical tests. NeoGenomics has purchased a UG 100 sequencer that will be installed in its innovation center in Cambridge, UK.

      4/29/25 8:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Reports First Quarter 2025 Results

      Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

      4/29/25 7:30:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    $NEO
    Financials

    Live finance-specific insights

    See more
    • NeoGenomics Reports First Quarter 2025 Results

      Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

      4/29/25 7:30:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) o

      4/8/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

      NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics' commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country. Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its rev

      3/10/25 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tetrault Lynn A. bought $56,974 worth of shares (7,000 units at $8.14) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:26:57 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Kanovsky Stephen M bought $31,124 worth of shares (4,000 units at $7.78), increasing direct ownership by 11% to 40,090 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:24:53 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Chief Executive Officer Zook Anthony P. bought $148,919 worth of shares (18,900 units at $7.88) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/8/25 4:13:18 PM ET
      $NEO
      Precision Instruments
      Health Care

    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tetrault Lynn A. bought $56,974 worth of shares (7,000 units at $8.14) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:26:57 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Kanovsky Stephen M bought $31,124 worth of shares (4,000 units at $7.78), increasing direct ownership by 11% to 40,090 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:24:53 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Chief Executive Officer Zook Anthony P. bought $148,919 worth of shares (18,900 units at $7.88) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/8/25 4:13:18 PM ET
      $NEO
      Precision Instruments
      Health Care

    $NEO
    Leadership Updates

    Live Leadership Updates

    See more
    • NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

      Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

      3/18/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • PacBio Announces Appointment of Chris Smith to Board of Directors

      MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

      1/30/25 9:05:00 AM ET
      $NEO
      $PACB
      Precision Instruments
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Felicia Williams Joins NeoGenomics Board of Directors

      NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa

      11/14/24 8:10:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    $NEO
    SEC Filings

    See more
    • SEC Form 10-Q filed by NeoGenomics Inc.

      10-Q - NEOGENOMICS INC (0001077183) (Filer)

      4/29/25 4:06:41 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEOGENOMICS INC (0001077183) (Filer)

      4/29/25 7:35:33 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form DEFA14A filed by NeoGenomics Inc.

      DEFA14A - NEOGENOMICS INC (0001077183) (Filer)

      4/23/25 4:01:58 PM ET
      $NEO
      Precision Instruments
      Health Care

    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • NeoGenomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded NeoGenomics from Outperform to Market Perform and set a new price target of $9.00

      4/30/25 8:08:08 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics downgraded by The Benchmark Company

      The Benchmark Company downgraded NeoGenomics from Buy to Hold

      1/13/25 8:42:07 AM ET
      $NEO
      Precision Instruments
      Health Care
    • Jefferies initiated coverage on NeoGenomics with a new price target

      Jefferies initiated coverage of NeoGenomics with a rating of Buy and set a new price target of $22.00

      12/10/24 9:06:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      11/14/24 1:28:29 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by NeoGenomics Inc.

      SC 13G - NEOGENOMICS INC (0001077183) (Subject)

      2/14/24 10:04:34 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      2/13/24 5:09:41 PM ET
      $NEO
      Precision Instruments
      Health Care